179 related articles for article (PubMed ID: 31124943)
1. High/positive expression of ERCC1 predicts poor treatment response and survival prognosis in nasopharyngeal carcinoma: A systematic meta-analysis from 21 studies.
Yang L; Wei W; Zhou L; Wang J; Hu G
Medicine (Baltimore); 2019 May; 98(21):e15641. PubMed ID: 31124943
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.
Liu T; Li Y; Song J; Li B; Wang R; Huang T; Qin Y
Cancer Control; 2024; 31():10732748241251562. PubMed ID: 38716503
[TBL] [Abstract][Full Text] [Related]
3. Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?
Aksoy A; Elkiran ET; Harputluoglu H; Dagli AF; Isikdogan A; Urakci Z
J Cancer Res Ther; 2019; 15(3):550-555. PubMed ID: 31169219
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Role of Programmed Death-Ligand 1 in Nasopharyngeal Carcinoma.
Wotman M; Herman SW; Costantino P; Tham T
Laryngoscope; 2020 Nov; 130(11):2598-2606. PubMed ID: 32112431
[TBL] [Abstract][Full Text] [Related]
6. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Shen C; Chen L; Fu J; Lin H
J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma.
Jin H; Xie X; Wang H; Hu J; Liu F; Liu Z; Zhou J; Zhang Y; Xi X; Hu B; Liao Y; Tang J
PLoS One; 2014; 9(7):e101256. PubMed ID: 25025378
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.
Hui EP; Ma BB; Chan KC; Chan CM; Wong CS; To KF; Chan AW; Tung SY; Ng WT; Cheng AC; Lee VH; Chan SL; Loong HH; Kam MK; Leung SF; Ho R; Mo F; Ngan RK; Chan AT
Cancer; 2015 Aug; 121(16):2720-9. PubMed ID: 25946469
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
11. Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis.
Hong X; Wang G; Xu G; Shi W; Wang T; Rong Z; Mo C
Medicine (Baltimore); 2022 Jan; 101(3):e28507. PubMed ID: 35060503
[TBL] [Abstract][Full Text] [Related]
12. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Huang PY; Li Y; Mai HQ; Luo RZ; Cai YC; Zhang L
Oral Oncol; 2012 Oct; 48(10):964-968. PubMed ID: 22571922
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
Mol Biol Rep; 2012 Jun; 39(6):6933-42. PubMed ID: 22302397
[TBL] [Abstract][Full Text] [Related]
14. Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma.
Xu S; Yu Y; Rong J; Hu D; Zhang L; Fu S; Yang H; Fan J; Yang L; Wu J
Oncotarget; 2017 May; 8(19):31355-31367. PubMed ID: 28404895
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of cyclin D1 can act as an independent prognostic marker for longer survival time in human nasopharyngeal carcinoma.
Liu Y; Liu Q; Wang Z; Chen M; Chen Y; Li X; Huang D; Fan S; Xiong W; Li G; Zhang W
J Clin Lab Anal; 2020 Aug; 34(8):e23298. PubMed ID: 32697404
[TBL] [Abstract][Full Text] [Related]
16. Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?
Chan SH; Cheung FM; Ng WT; Choi CW; Cheung KN; Yiu KH; Lee AW
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1414-20. PubMed ID: 20605357
[TBL] [Abstract][Full Text] [Related]
17. Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment.
Jagdis A; Phan T; Klimowicz AC; Laskin JJ; Lau HY; Petrillo SK; Siever JE; Thomson TA; Magliocco AM; Hao D
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1340-5. PubMed ID: 23182703
[TBL] [Abstract][Full Text] [Related]
18. Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma.
Benzeid R; Gihbid A; Tawfiq N; Benchakroun N; Bendahhou K; Benider A; Guensi A; El Benna N; Filali Maltouf A; Attaleb M; Chaoui I; Khyatti M; El Mzibri M
Asian Pac J Cancer Prev; 2023 Jan; 24(1):93-99. PubMed ID: 36708557
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of prognostic nutritional index in nasopharyngeal carcinoma: A meta-analysis containing 4511 patients.
Tu X; Ren J; Zhao Y
Oral Oncol; 2020 Nov; 110():104991. PubMed ID: 32919361
[TBL] [Abstract][Full Text] [Related]
20. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
